Shares are trading at $14.25 much higher than the 50 day moving average which is $10.37 and which is quite a bit higher than the 200 day moving average of $9.34. The 50 day moving average was up by +37.39% and the 200 day average moved up $4.91. Trading volume for iRadimed Corporation was 34K in the last trading session. Trading volume was up 20.88% over the stocks average daily volume.
Investors are feeling more bullish on shares of the company lately if you consider the decrease in short interest. The firm had a fall in short interest of -1.61% as of October 13, 2017 from the last reporting period. Short interest fell 13,145 over that timeframe. Days to cover increased 2.0 to 73.0 and the short interest percentage is 0.08% as of October 13.
A few notable investment firms have updated their holdings. As of the end of the quarter Creative Planning had sold 2,027 shares trimming its position 80.2%. The value of the investment in iRadimed Corporation decreased from $55,000 to $4,000 decreasing 92.7% quarter to quarter. As of quarter end Neuberger Berman Group LLC had acquired a total of 3,500 shares growing its holdings by 23.3%. The value of the investment in (IRMD) went from $134,000 to $159,000 a change of 18.7% since the last quarter.
Spark Investment Management LLC trimmed its investment by shedding 4,600 shares a decrease of 6.4%. Spark Investment Management LLC owns 66,900 shares with a value of $575,000. The value of the position overall is down by 9.6%. As of the end of the quarter Ubs Group Ag had acquired 1,288 shares growing its stake by 926.6%. The value of the total investment in iRadimed Corporation went from $1,000 to $12,000 a change of $11,000 quarter over quarter.
On July 31, 2017 the stock rating was set at “Buy” by Roth Capital which was a boost from the previous “Neutral” rating.
The P/E ratio is currently 59.62 and the market cap is 150.79M. In the latest earnings report the EPS was $0.24 and is estimated to be $0.13 for the current year with 10,582,000 shares presently outstanding. Next quarter’s EPS is forecasted at $0.03 and the next full year EPS is projected to be $0.23.
IRADIMED CORPORATION (IRADIMED), launched on April 8, 2014, develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. The Business’s MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous parts and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. Each system consists of MRidium MRI compatible IV infusion pump, non-magnetic mobile stand and disposable IV tubing sets..Advertisement